Form 4: Akoya Biosciences CEO Brian McKelligon Sells Shares Under 10b5-1 Trading Plan

Akoya Biosciences' CEO, Brian McKelligon, sold 7,500 shares of common stock at an average price of $4.938 per share on March 13, 2024, under a pre-arranged trading plan.

Summary

• On March 13, 2024, Brian McKelligon, the President and CEO of Akoya Biosciences, Inc., sold 7,500 shares of the company's common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on August 16, 2023.
• The shares were sold at a weighted average price of $4.938, with individual transaction prices ranging from $4.81 to $5.08.
• Following the transaction, McKelligon directly owns 224,368 shares of Akoya Biosciences.
• The reporting person is committed to providing full information regarding the number of shares sold at each separate price within the specified range upon request.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan. It doesn't necessarily reflect a positive or negative outlook on the company's future.

Industry Context

This filing is a routine disclosure of insider trading activity. It's common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The market will likely interpret this as a neutral event unless the size of the sale is unusually large or coincides with other negative news.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder confidence, but is unlikely to be significant given the existence of the 10b5-1 trading plan.

Key Dates